Marcos Ramos-Benitez to Aminopyridines
This is a "connection" page, showing publications Marcos Ramos-Benitez has written about Aminopyridines.
Connection Strength
1.220
-
Ramos-Benitez MJ, Miao R, Rivera-Torres AP, Lacourt-Ventura M, Malavez-Cajigas SJ, Tian X, Teague HL, De Jesus-Rojas W, Reger R, Suffredini AF, King C, Nathan SD, Childs RW, Strich JR. Surfactant Protein D and Club Cell Secretory Protein as Biomarkers of Disease Severity and Fostamatinib Efficacy in Severe COVID-19. Crit Care Explor. 2025 Apr 01; 7(4):e1252.
Score: 0.912
-
Warner S, Teague HL, Ramos-Benitez MJ, Panicker S, Allen K, Gairhe S, Moyer T, Parachalil Gopalan B, Douagi I, Shet A, Kanthi Y, Suffredini AF, Chertow DS, Strich JR. R406 reduces lipopolysaccharide-induced neutrophil activation. Cell Immunol. 2024 Sep-Oct; 403-404:104860.
Score: 0.217
-
Strich JR, Tian X, Samour M, King CS, Shlobin O, Reger R, Cohen J, Ahmad K, Brown AW, Khangoora V, Aryal S, Migdady Y, Kyte JJ, Joo J, Hays R, Collins AC, Battle E, Valdez J, Rivero J, Kim IH, Erb-Alvarez J, Shalhoub R, Chakraborty M, Wong S, Colton B, Ramos-Benitez MJ, Warner S, Chertow DS, Olivier KN, Aue G, Davey RT, Suffredini AF, Childs RW, Nathan SD. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial. Clin Infect Dis. 2022 08 24; 75(1):e491-e498.
Score: 0.048
-
Strich JR, Ramos-Benitez MJ, Randazzo D, Stein SR, Babyak A, Davey RT, Suffredini AF, Childs RW, Chertow DS. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J Infect Dis. 2021 03 29; 223(6):981-984.
Score: 0.043